Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Veterinary Microbiology

• Publication date

  2010-11-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vetmic.2010.03.024PMID 20888151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic

  2009cited by this paper
• Current status and progress of prepandemic and pandemic influenza vaccine development

  2009cited by this paper
• Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

  2009cited by this paper
• Emergence and pandemic potential of swine-origin H1N1 influenza virus

  2009cited by this paper
• Immunogenicity and Protective Efficacy of a Live Attenuated H5N1 Vaccine in Nonhuman Primates

  2009cited by this paper
• Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

  2009cited by this paper
• Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.

  2009cited by this paper
• Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines.

  2009cited by this paper
• Poly (I:C) induced immune response in lymphoid tissues involves three sequential waves of type I IFN expression.

  2009cited by this paper
• Emulsion-based adjuvants for influenza vaccines

  2009cited by this paper
• A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

  2008cited by this paper
• Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

  2008cited by this paper
• Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice

  2008cited by this paper
• Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

  2008cited by this paper
• Pandemic H5N1 influenza vaccine development: an update

  2008cited by this paper
• Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.

  2008cited by this paper
• Safety of MF59 adjuvant.

  2008cited by this paper
• Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

  2008cited by this paper
• Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.

  2007cited by this paper
• Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

  2007cited by this paper
• Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.

  2007cited by this paper
• Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.

  2007cited by this paper
• The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

  2006cited by this paper
• Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection

  2005cited by this paper
• Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

  2003cited by this paper
• Strategies of immunization against mucosal infections.

  2000cited by this paper
• Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens.

  1991cited by this paper

• Development of universal influenza vaccines: strategies for broadly cross-reactive influenza vaccine responses

  2025cites this paper
• Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice

  2025cites this paper
• A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

  2017cites this paper
• CpG Oligodeoxynucleotides Facilitate Delivery of Whole Inactivated H9N2 Influenza Virus via Transepithelial Dendrites of Dendritic Cells in Nasal Mucosa

  2015cites this paper
• Vaccine technologies against avian influenza: current approaches and new directions.

  2014cites this paper
• Proteínas recombinantes útiles para la prevención de la infección por Bordetella pertussis

  2014cites this paper
• Synthetic nanoparticle-based vaccines against respiratory pathogens

  2013cites this paper
• Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine

  2013cites this paper
• Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.

  2013cites this paper
• Multiple-Clade H5N1 Influenza Split Vaccine Elicits Broad Cross Protection against Lethal Influenza Virus Challenge in Mice by Intranasal Vaccination

  2012cites this paper
• Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice.

  2012cites this paper
• The Cholera Toxin as a Biotechnological Tool

  2012cites this paper
• Effect of intranasal immunization with inactivated avian influenza virus on local and systemic immune responses in ducks.

  2012cites this paper
• Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.

  2011cites this paper
• The mucosal and systemic immune responses elicited by a chitosan‐adjuvanted intranasal influenza H5N1 vaccine

  2011cites this paper